Following publication of these RCTs, the target Hb for patients with CKD was lowered to 100–120 g/L in UK Renal Association and National Institute for Health and Care Excellence (NICE) treatment guidelines [2, 16]. This evidence concerns the gene GSTM1 and chronic kidney disease.